2023
Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays
Al-Bawardy B, Jenkins S, Snyder M, Frinack J, Ladwig P, Loftus E, Willrich M. Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays. Clinical Biochemistry 2023, 119: 110618. PMID: 37507083, DOI: 10.1016/j.clinbiochem.2023.110618.Peer-Reviewed Original ResearchConceptsInflammatory bowel disease patientsBowel disease patientsEndoscopic healingClinical remissionDisease patientsMcg/Normal serum C-reactive proteinDrug monitoringSerum C-reactive proteinLC-MS/MSInfliximab drug levelsFavorable clinical outcomeC-reactive proteinTherapeutic drug monitoringIBD patientsNormal CRPClinical outcomesDrug levelsPatientsECLIARemissionDifferent assaysOutcomesMcgAssays
2009
Relationship of dietary micronutrient intake with fasting plasma glucose and HbA1c: DIALBEST Trial Preliminary Results
Chhabra J, Vega‐López S, D'Agostino D, Fernandez M, Segura‐Pérez S, Damio G, Pérez‐Escamilla R. Relationship of dietary micronutrient intake with fasting plasma glucose and HbA1c: DIALBEST Trial Preliminary Results. The FASEB Journal 2009, 23: 550.3-550.3. DOI: 10.1096/fasebj.23.1_supplement.550.3.Peer-Reviewed Original ResearchPlausible reportersImplausible reportersPlasma glucoseEnergy intakeTotal sampleDietary micronutrient intakeType 2 diabetesVit KDietary recallsLatino patientsVit DFolate intakeMicronutrient intakeDietary micronutrientsHealth disparitiesVit B6FPGDemographic informationIntakePatientsDlHartford CountyMcgRetinolGlucose
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply